Clinical outcome and safety of rituximab therapy for pemphigoid diseases

J Am Acad Dermatol. 2020 May;82(5):1237-1239. doi: 10.1016/j.jaad.2019.11.023. Epub 2019 Nov 16.

Authors

Napatra Tovanabutra¹, Aimee S Payne²

Affiliations

¹ Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Internal Medicine, Division of Dermatology, Chiang Mai University, Chiang Mai, Thailand.
² Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: paynea@pennmedicine.upenn.edu.

PMID: 31738960
DOI: 10.1016/j.jaad.2019.11.023

No abstract available

Publication types

Letter

MeSH terms

Dose-Response Relationship, Drug
Follow-Up Studies
Humans
Immunologic Factors / administration & dosage*
Immunologic Factors / adverse effects
Pemphigoid, Benign Mucous Membrane / drug therapy*
Pemphigoid, Benign Mucous Membrane / immunology
Pemphigoid, Bullous / drug therapy*
Pemphigoid, Bullous / immunology
Pennsylvania
Recurrence
Remission Induction / methods
Rituximab / administration & dosage*
Rituximab / adverse effects
Treatment Outcome

Substances

Immunologic Factors
Rituximab